Phase 2 Endometrial Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 70 years old
• People who have been diagnosed with cervical cancer confirmed by tissue testing, specifically squamous carcinoma, adenocarcinoma, or adenosquamous carcinoma
• People whose cervical cancer has been classified as 2018 FIGO stage IIIC2
• People who have at least one tumour that can be measured using standard imaging criteria (known as RECIST 1.1)
• People who are generally well enough to carry out light activity and care for themselves (rated 0 or 1 on a standard health performance scale)
• People whose cancer has not spread to distant parts of the body (no metastatic disease)
• People who are expected to live at least 6 months
• People whose blood counts and organ function meet specific healthy ranges, including sufficient levels of haemoglobin, white blood cells, platelets, and albumin, and normal liver and kidney function values (confirm specific values with trial site)
• Women who are post-menopausal, or women of childbearing potential who have a negative pregnancy test, are not breastfeeding, and agree to use effective contraception throughout the study
• People who voluntarily agree to take part and sign a consent form

Who may not be able to join:

• People diagnosed with any other cancer in the past 5 years
• People with a known allergy to any ingredient in the study drug
• People with a weakened immune system, whether from birth or due to a condition such as HIV infection
• People with an active or suspected autoimmune disease (such as lung inflammation, eye inflammation, bowel inflammation, hepatitis, arthritis, kidney inflammation, or thyroid problems), a history of vitiligo, or asthma that requires reliever medication to manage
• People with an active infection that requires treatment with systemic medication
• People who have previously been treated with certain immune checkpoint drugs (such as PD-1, PD-L1, or CTLA-4 targeted therapies)
• People who still have significant side effects (grade 2 or higher) from any previous cancer treatment
• People with a history of heart attack, stroke, unstable chest pain, severe heart failure, or deep vein blood clots
• People with wounds or broken bones that have not healed over a long period, or who have had major surgery, serious injury, a fracture, or an ulcer within the past 4 weeks
• Women who are pregnant or breastfeeding
• People whose cancer has spread to distant parts of the body (metastatic disease)
• People with liver or kidney insufficiency
• People with a history of substance abuse involving psychotropic drugs that has not been resolved, or people with a diagnosed mental health disorder
• People who have taken part in another clinical drug trial within the past 4 weeks
• People with other illnesses or abnormal test results that the trial investigator believes would interfere with receiving the study treatment
• People the trial investigator believes would not receive meaningful benefit from the study

Important: Always verify eligibility with the trial site directly before applying.